Transplacental rotavirus IgG interferes with immune response to live oral rotavirus vaccine ORV-116E in Indian infants

Vaccine

Volumn 32, Issue 6, 2014, Pages 651-656

  Appaiahgari, Mohan Babu ^a   Glass, Roger ^b   Singh, Shakti ^c   Taneja, Sunita ^c   Rongsen Chandola, Temsunaro ^c   Bhandari, Nita ^c   Mishra, Sukhdev ^d   Vrati, Sudhanshu ^a,e  

^a Translational Health Science and Technology Institute   (India)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c SOCIETY FOR APPLIED STUDIES   (India)

^d Clinical Development Services Agency   (India)

^e NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

Dose; IgA; Maternal antibody; Rotavirus; Seroconversion; Vaccine

Indexed keywords

IMMUNOGLOBULIN G; ORV 116E VACCINE; PLACEBO; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INDIAN; INFANT; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ROTAVIRUS; SEROCONVERSION; TRANSPLACENTAL DRUG ADMINISTRATION; VACCINATION; VIRUS IMMUNITY; VIRUS INTERFERENCE;

DOSE; IGA; MATERNAL ANTIBODY; ROTAVIRUS; SEROCONVERSION; VACCINE;

ANTIBODIES, VIRAL; ANTIBODY FORMATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INDIA; INFANT; PREGNANCY; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 84893007379     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.12.017     Document Type: Article

References (40)

1. World Health Organization Global and national estimates of deaths under age five attributable to rotavirus infection 2004, World Health Organization, Geneva, Switzerland, www.who.int/entity/immunization_monitoring/burden/Global_national_estimates_2004_deaths_under_age_five_attributable_to_rotavirus_infection_2004.pdf.
2. World Health Organization Global networks for surveillance of rotavirus gastroenteritis. Wkly Epidemiol Rec 2001-2008, 83:421-425.
3. Patel M., Shane A.L., Parashar U.D., Jiang B., Gentsch J.R., Glass R.I. Oral rotavirus vaccines: how well will they work where they are needed mostα. J Infect Dis 2009, 200(Suppl 1):S39-S48.
4. Madhi S.A., Cunliffe N.A., Steele D., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362(4):289-298.
5. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(1):11-22.
6. Vesikari T., Matson D.O., Dennehy P., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(1):23-33.
7. Armah G.E., Sow S.O., Breiman R.F., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376(9741):606-614.
8. Zaman K., Dang D.A., Victor J.C., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376(9741):615-623.
9. Cadranel S., Zeglache S., Jonckheer T., et al. Factors affecting antibody response of newborns to repeated administrations of the rotavirus vaccine RIT 4237. J Pediatr Gastroenterol Nutr 1987, 6(4):525-528.
10. Rimer H.C., Wasserman S.S., Flores J., Pichichero M.E., Losonsky G.A. Rotavirus-specific breast milk antibody in two populations and possible correlates of interference with rhesus rotavirus vaccine seroconversion. J Infect Dis 1992, 165(5):826-830.
11. Siegrist C.A. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 2003, 21(24):3406-3412.
12. Nguyen T.V., Yuan L., Azevedo M.S., et al. High titers of circulating maternal antibodies suppress effector and memory B-cell responses induced by an attenuated rotavirus priming and rotavirus-like particle-immunostimulating complex boosting vaccine regimen. Clin Vaccine Immunol 2006, 13(4):475-485.
13. Chan J., Nirwati H., Triasih R., et al. Maternal antibodies to rotavirus: could they interfere with live rotavirus vaccines in developing countriesα. Vaccine 2011, 29(6):1242-1247.
14. Das B.K., Gentsch J.R., Cicirello H.G., et al. Characterization of rotavirus strains from newborns in New Delhi, India. J Clin Microbiol 1994, 32(7):1820-1822.
15. Gentsch J.R., Das B.K., Jiang B., Bhan M.K., Glass R.I. Similarity of the VP4 protein of human rotavirus strain 116E to that of the bovine B223 strain. Virology 1993, 194(1):424-430.
16. Bhandari N., Sharma P., Glass R.I., et al. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial. Vaccine 2006, 24(31-32):5817-5823.
17. Glass R.I., Bhan M.K., Ray P., et al. Development of candidate rotavirus vaccines derived from neonatal strains in India. J Infect Dis 2005, 192(Suppl 1):S30-S35.
18. Jayashree S., Bhan M.K., Kumar R., Raj P., Glass R., Bhandari N. Serum and salivary antibodies as indicators of rotavirus infection in neonates. J Infect Dis 1988, 158(5):1117-1120.
19. Bhan M.K., Lew J.F., Sazawal S., Das B.K., Gentsch J.R., Glass R.I. Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. J Infect Dis 1993, 168(2):282-287.
20. Jayashree S., Bhan M.K., Raj P., et al. Neonatal rotavirus infection and its relation to cord blood antibodies. Scand J Infect Dis 1988, 20(3):249-253.
21. Bhandari N., Sharma P., Taneja S., et al. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial. J Infect Dis 2009, 200(3):421-429.
22. Narang A., Bose A., Pandit A.N., et al. Immunogenicity, reactogenicity, and safety of human rotavirus vaccine (RIX4414) in Indian infants. Hum Vaccine 2009, 5(6):414-419.
23. Patel M., Glass R.I., Jiang B., Santosham M., Lopman B., Parashar U. A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy. J Infect Dis 2013, 208(2):284-294.
24. Hjelt K., Grauballe P.C., Paerregaard A., Nielsen O.H., Krasilnikoff P.A. Protective effect of preexisting rotavirus-specific immunoglobulin A against naturally acquired rotavirus infection in children. J Med Virol 1987, 21(1):39-47.
25. Brussow H., Werchau H., Liedtke W., et al. Prevalence of antibodies to rotavirus in different age-groups of infants in Bochum, West Germany. J Infect Dis 1988, 157(5):1014-1022.
26. O'Ryan M.L., Matson D.O., Estes M.K., Pickering L.K. Anti-rotavirus G type-specific and isotype-specific antibodies in children with natural rotavirus infections. J Infect Dis 1994, 169(3):504-511.
27. Perez-Schael I., Gonzalez R., Fernandez R., et al. Epidemiological features of rotavirus infection in Caracas, Venezuela: implications for rotavirus immunization programs. J Med Virol 1999, 59(4):520-526.
28. Zheng B.J., Ma G.Z., Tam J.S., et al. The effects of maternal antibodies on neonatal rotavirus infection. Pediatr Infect Dis J 1991, 10(11):865-868.
29. Black R.E., Greenberg H.B., Kapikian A.Z., Brown K.H., Becker S. Acquisition of serum antibody to Norwalk Virus and rotavirus and relation to diarrhea in a longitudinal study of young children in rural Bangladesh. J Infect Dis 1982, 145(4):483-489.
30. Perkins F.T., Yetts R., Gaisford W. A comparison of the responses of 100 infants to primary poliomyelitis immunization with two and with three doses of vaccine. Br Med J 1959, 1(5129):1083-1086.
31. Albrecht P., Ennis F.A., Saltzman E.J., Krugman S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr 1977, 91(5):715-718.
32. Nguyen T.V., Yuan L., Azevedo M.S., et al. Low titer maternal antibodies can both enhance and suppress B cell responses to a combined live attenuated human rotavirus and VLP-ISCOM vaccine. Vaccine 2006, 24(13):2302-2316.
33. Flores J., Perez-Schael I., Blanco M., et al. Reactogenicity and immunogenicity of a high-titer rhesus rotavirus-based quadrivalent rotavirus vaccine. J Clin Microbiol 1993, 31(9):2439-2445.
34. Santosham M., Moulton L.H., Reid R., et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr 1997, 131(4):632-638.
35. Dagan R., Amir J., Mijalovsky A., et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J 2000, 19(11):1045-1052.
36. Cutts F.T., Nyandu B., Markowitz L.E., et al. Immunogenicity of high-titre AIK-C or Edmonston-Zagreb vaccines in 3.5-month-old infants, and of medium- or high-titre Edmonston-Zagreb vaccine in 6-month-old infants, in Kinshasa, Zaire. Vaccine 1994, 12(14):1311-1316.
37. Rennels M.B., Glass R.I., Dennehy P.H., et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the national multicenter trial. United States rotavirus vaccine efficacy group. Pediatrics 1996, 97(1):7-13.
38. Vesikari T., Karvonen A., Korhonen T., et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 2004, 22(21-22):2836-2842.
39. Steele A.D., Tumbo J., Armah G.E., De Vos B. Comparison of two different regimens (two doses versus three doses) in terms of reactogenicity and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 in South African infants Program and Abstracts of the 9th International Symposium on Double Stranded RNA Viruses 2006, Cape Town, South Africa.
40. Lanata C.F., Midthun K., Black R.E., et al. Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. J Infect Dis 1996, 174(2):268-275.